NCT07148960View on ClinicalTrials.gov

Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Staphylococcus Aureus Bacteremia
Interventions
DRUG

Early Dual IV Antibiotic Therapy - MRSA

Participant given IV daptomycin plus ceftaroline dosing per standard of care. Oral rifampin may be added for participants with prosthetic material.

DRUG

Early Dual IV Antibiotic Therapy - MSSA

Participant given IV cefazolin plus ertapenem dosing per standard of care. Oral rifampin may be added for participants with prosthetic material.

DRUG

Single Agent IV Antibiotic Therapy - MRSA

Participant given one of the following IV therapies: daptomycin, vancomycin, or ceftaroline. Oral rifampin may be added for participants with prosthetic material.

DRUG

Single Agent IV Antibiotic Therapy - MSSA

Participant given one of the following IV therapies: cefazolin, oxacillin, or nafcillin. Oral rifampin may be added for participants with prosthetic material.

Trial Locations (1)

26506

West Virginia University, Morgantown

All Listed Sponsors
lead

West Virginia University

OTHER